 |
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Cytokine
|
 |
|
Title:
|
 |
Crystal structure of the extracellular domain of mouse rank ligand
|
|
Structure:
|
 |
Receptor activator of nuclear factor kappa b ligand. Chain: a, b, c. Fragment: extracellular domain (residues 157-316). Synonym: tumor necrosis factor ligand superfamily member 11, rankl, trance, opgl, odf. Engineered: yes. Mutation: yes
|
|
Source:
|
 |
Mus musculus. House mouse. Organism_taxid: 10090. Expressed in: escherichia coli. Expression_system_taxid: 562.
|
|
Biol. unit:
|
 |
Trimer (from
)
|
|
Resolution:
|
 |
|
2.20Å
|
R-factor:
|
0.226
|
R-free:
|
0.274
|
|
|
Authors:
|
 |
S.Ito,K.Wakabayashi,O.Ubukata,S.Hayashi,F.Okada,T.Hata
|
Key ref:
|
 |
S.Ito
et al.
(2002).
Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution.
J Biol Chem,
277,
6631-6636.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
11-Jul-01
|
Release date:
|
13-Mar-02
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
|
|
|
O35235
(TNF11_MOUSE) -
Tumor necrosis factor ligand superfamily member 11
|
|
|
|
Seq: Struc:
|
 |
 |
 |
316 a.a.
156 a.a.
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
|
|
|
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
membrane
|
1 term
|
 |
|
Biological process
|
immune response
|
1 term
|
 |
|
Biochemical function
|
tumor necrosis factor receptor binding
|
1 term
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Biol Chem
277:6631-6636
(2002)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution.
|
|
S.Ito,
K.Wakabayashi,
O.Ubukata,
S.Hayashi,
F.Okada,
T.Hata.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Bone remodeling involves the resorption of bone by osteoclasts and the synthesis
of bone matrix by osteoblasts. Receptor activator of NF-kappa B ligand (RANKL,
also known as ODF and OPGL), a member of the tumor necrosis factor (TNF) family,
triggers osteoclastogenesis by forming a complex with its receptor, RANK. We
have determined the crystal structure of the extracellular domain of mouse RANKL
at 2.2-A resolution. The structure reveals that the RANKL extracellular domain
is trimeric, which was also shown by analytical ultracentrifugation, and each
subunit has a beta-strand jellyroll topology like the other members of the TNF
family. A comparison of RANKL with TNF beta and TNF-related apoptosis-inducing
ligand (TRAIL), whose structures were determined to be in the complex form with
their respective receptor, reveals conserved and specific features of RANKL in
the TNF superfamily and suggests the presence of key residues of RANKL for
receptor binding.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 3.
Fig. 3. Mouse RANKL trimer and monomer. A, schematic view
of the mouse RANKL trimer shown with strands as
arrows and labeled by the notation of Eck and Sprang (12). The
three monomers are depicted in different colors. In this
orientation, the cell surface containing mouse RANKL is located
at the bottom of the figure. B, stereoview of the superposition
of the mouse RANKL, TNF , and TRAIL
monomers. The superposition was carried out using the program O
( 29). The figure shows the C traces with
mouse RANKL colored in red, TNF colored in
blue, and TRAIL colored in green. The numbers indicate the
N-terminal and C-terminal residues of mouse RANKL. The figures
were prepared with the programs Molscript (36) and Raster3D (37).
|
 |
Figure 6.
Fig. 6. Charge distribution for mouse RANKL, TNF , and TRAIL.
A, surface representation of the mRANKL trimer with each monomer
colored differently. B, ribbon drawing of the mRANKL monomer in
the same orientation as that in A. The three key residues
predicted to be important for receptor binding are shown as
ball-and-stick models. C, blue and red denote positive and
negative charges, respectively. The orientation is the same as
that of A and B. The figures were prepared with Insight II
(Molecular Simulations Inc.).
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from the ASBMB:
J Biol Chem
(2002,
277,
6631-6636)
copyright 2002.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
H.M.Ta,
G.T.Nguyen,
H.M.Jin,
J.Choi,
H.Park,
N.Kim,
H.Y.Hwang,
and
K.K.Kim
(2010).
Structure-based development of a receptor activator of nuclear factor-kappaB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis.
|
| |
Proc Natl Acad Sci U S A, 107,
20281-20286.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
R.Hanada,
T.Hanada,
and
J.M.Penninger
(2010).
Physiology and pathophysiology of the RANKL/RANK system.
|
| |
Biol Chem, 391,
1365-1370.
|
 |
|
|
|
|
 |
M.Baud'huin,
L.Duplomb,
S.Téletchéa,
C.Charrier,
M.Maillasson,
M.Fouassier,
and
D.Heymann
(2009).
Factor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survival.
|
| |
J Biol Chem, 284,
31704-31713.
|
 |
|
|
|
|
 |
S.K.Tat,
J.P.Pelletier,
C.R.Velasco,
M.Padrines,
and
J.Martel-Pelletier
(2009).
New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target?
|
| |
Keio J Med, 58,
29-40.
|
 |
|
|
|
|
 |
A.Leibbrandt,
and
J.M.Penninger
(2008).
RANK/RANKL: regulators of immune responses and bone physiology.
|
| |
Ann N Y Acad Sci, 1143,
123-150.
|
 |
|
|
|
|
 |
K.Aoki,
H.Saito,
C.Itzstein,
M.Ishiguro,
T.Shibata,
R.Blanque,
A.H.Mian,
M.Takahashi,
Y.Suzuki,
M.Yoshimatsu,
A.Yamaguchi,
P.Deprez,
P.Mollat,
R.Murali,
K.Ohya,
W.C.Horne,
and
R.Baron
(2006).
A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss.
|
| |
J Clin Invest, 116,
1525-1534.
|
 |
|
|
|
|
 |
D.A.Dossing,
and
P.H.Stern
(2005).
Receptor activator of NF-kappaB ligand protein expression in UMR-106 cells is differentially regulated by parathyroid hormone and calcitriol.
|
| |
J Cell Biochem, 95,
1029-1041.
|
 |
|
|
|
|
 |
E.M.Sordillo,
and
R.N.Pearse
(2003).
RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
|
| |
Cancer, 97,
802-812.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
|